Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

From VUCA to TACO: Thriving in a Chaotic World

From VUCA to TACO: Thriving in a Chaotic World Leaders...

Creat Customer

Articles by K. Hariram, Hanno Wolfram, Vivek Hattangadi, Salil Kallianpur, Amit Jain, Dr. Palakodeti Ratnakar, and Pankaj Mehrotra

How to Influence Patients to Adopt Healthy Lifestyle or Improve Adherence?

One of the many ways of influencing patients to...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Dr. Rishubh Gupta has been appointed Head of Subregion Africa for Roche Diagnostics

Dr. Rishubh Gupta has been appointed Head of Subregion...

Marketing

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Dr. Rishubh Gupta has been appointed Head of Subregion Africa for Roche Diagnostics

Dr. Rishubh Gupta has been appointed Head of Subregion...

Policies/Sales

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Dr. Rishubh Gupta has been appointed Head of Subregion Africa for Roche Diagnostics

Dr. Rishubh Gupta has been appointed Head of Subregion...

Strategy

Simon Rosof has been appointed Head of Asia Pacific for Bayer Pharmaceuticals

Simon Rosof has been appointed Head of Asia Pacific...

The Wealth of Pharma Nations: Top 25 Pharma Blockbusters

The economic footprint of a truly historic pharmaceutical blockbuster...

Oxytocin Maternal Deaths in Kota: Death in a Vial

When a vial contains only water, the failure is...

Innovation Without Access to Millions of Poor People is Unethical

What the Trikafta Stand-Off Teaches Us About the Future...

Dr. Rishubh Gupta has been appointed Head of Subregion Africa for Roche Diagnostics

Dr. Rishubh Gupta has been appointed Head of Subregion...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

Dr. Rishubh Gupta has been appointed Head of Subregion Africa for Roche Diagnostics

Dr. Rishubh Gupta has been appointed Head of Subregion...

Astra Zeneca Tops Indian Pharma in New Introductions 2024

Analysis of Indian Pharmaceutical Market (IPM) – 2024 This data...

The Rise and Fall of A.H. Robins Company: A Tale of Innovation Marred by One Acquisition

A.H. Robins Company was a formidable name in the...

A Cardiologist Recounts his Fightback from a Near Death Covid19 Infection

In the lockdown, while I was on regular OPD and ICU rounds at a COVID hospital, I started noticing some mild symptoms of the Coronavirus infection. Being in the medical field and considering the severity of the pandemic situation then, I was very careful and cautious, and observed the symptoms closely. The symptoms persisted and I had to self-quarantine until the medical test reports came. It was important for me to isolate myself from the rest of the medical team and prevent the spread of the virus. Finally, the report came: I was COVID positive! Stunned and slightly devastated; I broke the news to my family who could not believe it either. As a doctor, I could only treat, comfort and empathize with the COVID patients undergoing treatment; completely isolated from their loved ones. But now, I could actually feel the uncertainty of the situation. I was hospitalized and continued to experience body-ache during the admission. It was a stressful situation where I felt anxious and stressed about everything. My CT scan reports showed mild lung infection on the day of admission but as the cytokines storm developed, my lungs were 76 % damaged in 3-5 days and I was short of breath and my oxygen level deteriorated to less than 80. I was shifted to an ICU with high-flow oxygen and was on a BiPap machine which I had purchased a few weeks ago for the hospital and never imagined that I would be using myself one day.